Pazopanib for the treatment of renal cell carcinoma and other malignancies.
Pazopanib (GW-786034) is a second-generation multitargeted tyrosine kinase inhibitor against VEGFR1, -2 and -3, PDGFRalpha, PDGFRbeta and c-Kit. Preclinical evaluation has revealed excellent anti-angiogenic and antitumor activity in several tumors. A phase II clinical trial of pazopanib in untreated or cytokine/bevacizumab-pretreated renal cell carcinoma (RCC) has demonstrated promising activity accompanied by a favorable toxicity profile. A placebo-controlled phase III trial in untreated or cytokine-treated patients with RCC demonstrated a significant improvement in progression-free survival. Ongoing trials are further evaluating pazopanib in a variety of other malignancies.
Sonpavde
Guru
G
Texas Oncology, USA.
Hutson
Thomas E
TE
Sternberg
Cora N
CN
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D007191:Indazoles; D007680:Kidney Neoplasms / Q000188:drug therapy*; D009369:Neoplasms / Q000188:drug therapy; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000008:administration & dosage* / Q000494:pharmacology; D013449:Sulfonamides / Q000008:administration & dosage* / Q000494:pharmacology
D000970:Antineoplastic Agents; D007191:Indazoles; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; C516667:pazopanib; D011505:Protein-Tyrosine Kinases